- Home
- FIGX vs CVRX Comparison
FIGX vs CVRX Comparison
Compare FIGX & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGX
- CVRX
- Stock Information
- Founded
- FIGX 2025
- CVRX 2000
- Country
- FIGX United States
- CVRX United States
- Employees
- FIGX N/A
- CVRX N/A
- Industry
- FIGX
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- FIGX
- CVRX Health Care
- Exchange
- FIGX Nasdaq
- CVRX Nasdaq
- Market Cap
- FIGX 193.7M
- CVRX 203.9M
- IPO Year
- FIGX 2025
- CVRX 2021
- Fundamental
- Price
- FIGX $10.00
- CVRX $8.75
- Analyst Decision
- FIGX
- CVRX Buy
- Analyst Count
- FIGX 0
- CVRX 7
- Target Price
- FIGX N/A
- CVRX $14.00
- AVG Volume (30 Days)
- FIGX 5.1K
- CVRX 194.9K
- Earning Date
- FIGX 01-01-0001
- CVRX 10-28-2025
- Dividend Yield
- FIGX N/A
- CVRX N/A
- EPS Growth
- FIGX N/A
- CVRX N/A
- EPS
- FIGX N/A
- CVRX N/A
- Revenue
- FIGX N/A
- CVRX $54,652,000.00
- Revenue This Year
- FIGX N/A
- CVRX $11.32
- Revenue Next Year
- FIGX N/A
- CVRX $18.58
- P/E Ratio
- FIGX N/A
- CVRX N/A
- Revenue Growth
- FIGX N/A
- CVRX 23.11
- 52 Week Low
- FIGX $9.95
- CVRX $4.30
- 52 Week High
- FIGX $10.05
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- FIGX N/A
- CVRX 66.43
- Support Level
- FIGX N/A
- CVRX $7.52
- Resistance Level
- FIGX N/A
- CVRX $8.12
- Average True Range (ATR)
- FIGX 0.00
- CVRX 0.46
- MACD
- FIGX 0.00
- CVRX 0.14
- Stochastic Oscillator
- FIGX 0.00
- CVRX 91.29
About FIGX FIGX Capital Acquisition Corp. Class A Ordinary Share
FIGX Capital Acquisition Corp is a blank check company.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.